Ir para o conteúdo principal

Forte Biosciences (NYSE: FBRX) — Perfil da empresa, notícias e dados financeiros

Logo de Forte Biosciences
FBRX Forte Biosciences
Forte Biosciences primary media
Perfil da empresa

Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) focuses on advancing the science and treatment of patients battling inflammatory skin diseases. Using a combination of biotechnology and a deep understanding of dermatological conditions, Forte is committed to developing innovative therapies. The company's projects primarily revolve around leveraging their proprietary technology platforms to create treatments that are both effective and safe for patients suffering from conditions such as psoriasis, atopic dermatitis, and other inflammatory skin diseases. At the core of Forte's objectives, is the ambition to significantly improve the quality of life for patients by offering novel solutions that address unmet clinical needs in the dermatology space. Their efforts are directed towards not only discovering and developing new drugs but also ensuring these advancements are accessible to the individuals who need them most.

Resumo

Public USParticipação acionária
2007Ano de fundação
9Funcionários
Dallas, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Dallas, US

Produtos e/ou serviços de Forte Biosciences

  • Development of a novel topical therapy aimed at treating inflammatory skin diseases by targeting the immune system.
  • Research into precision biologics for addressing severe immune disorders.
  • Collaboration with academic institutions to discover new immunomodulatory compounds.
  • Partnership with technology firms to enhance drug delivery methods for skin conditions.
  • Initiative to leverage artificial intelligence for predicting drug efficacy in dermatological treatments.
  • Contribution to clinical trials focused on advancing therapies for autoimmune skin diseases.

equipe executiva do Forte Biosciences

  • Dr. Paul A. Wagner Ph.D.CEO, President & Chairman
  • Mr. Antony A. Riley CPAChief Financial Officer
  • Dr. Barbara K. Finck M.D.Chief Medical Clinician & Director
  • Mr. Christopher RoenfeldtChief Operating Officer

Principais indicadores financeiros

Resultados divulgados pela Forte Biosciences, em USD.

Receita e lucro anuais da Forte Biosciences
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-70,7 mi-69,4 mi
0-36,6 mi-35,5 mi
0-32,5 mi-31,5 mi
0-13,9 mi-13,9 mi